{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:50:02Z","timestamp":1789732202241,"version":"4.0.1"},"reference-count":196,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.556610","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T06:53:14Z","timestamp":1602658394000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Katerina","family":"Trajanoska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivadeneira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5863\/1551-6776-18.1.8","article-title":"Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis","volume":"18","author":"Condren","year":"2013","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with leber congenital amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature."},{"key":"B6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Prim."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e10174","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis imperfecta: new perspectives from clinical and translational research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1210\/jc.2017-01127","article-title":"Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group","volume":"102","author":"Wu","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.beem.2018.06.003","article-title":"Sclerosing bone dysplasias","volume":"32","author":"Boudin","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","author":"Estrada","year":"2012","journal-title":"Nat Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.1088757","article-title":"Gene targeting in stem cells from individuals with osteogenesis imperfecta","volume":"303","author":"Chamberlain","year":"2004","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.mt.6300339","article-title":"Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta","volume":"16","author":"Chamberlain","year":"2008","journal-title":"Mol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/mt.2011.209","article-title":"Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs","volume":"20","author":"Deyle","year":"2012","journal-title":"Mol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101453","DOI":"10.1016\/j.scr.2019.101453","article-title":"The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c","volume":"38","author":"Howden","year":"2019","journal-title":"Stem Cell Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101449","DOI":"10.1016\/j.scr.2019.101449","article-title":"Generation of a heterozygous COL1A1 (c","volume":"37","author":"Hosseini Far","year":"2019","journal-title":"Stem Cell Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2010-05-287565","article-title":"Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties","volume":"117","author":"Vanleene","year":"2011","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/scd.2013.0132","article-title":"Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta","volume":"23","author":"Jones","year":"2014","journal-title":"Stem Cells Dev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience","volume":"3","author":"G\u00f6therstr\u00f6m","year":"2014","journal-title":"Stem Cells Transl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41431-019-0387-4","article-title":"Stakeholder views and attitudes towards prenatal and postnatal transplantation of fetal mesenchymal stem cells to treat osteogenesis imperfecta","volume":"27","author":"Hill","year":"2019","journal-title":"Eur J Hum Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7150\/ijms.5.361","article-title":"Allele dependent silencing of COL1A2 using small interfering RNAs","volume":"5","author":"Lindahl","year":"2008","journal-title":"Int J Med Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ejhg.2013.198","article-title":"Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta","volume":"22","author":"Rousseau","year":"2014","journal-title":"Eur J Hum Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","article-title":"Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene","volume":"10","author":"Cleiren","year":"2001","journal-title":"Hum Mol Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2015.12.021","article-title":"Genetic control of bone mass","volume":"432","author":"Boudin","year":"2016","journal-title":"Mol Cell Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s004310050751","article-title":"Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome","volume":"156","author":"Ismail","year":"1997","journal-title":"Eur J Pediatr."},{"key":"B28","unstructured":"SobacchiC\n            VillaA\n            SchulzA\n            KornakU\n          CLCN7-Related Osteopetrosis1993"},{"key":"B29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2013.137","article-title":"Osteopetrosis: genetics, treatment and new insights into osteoclast function","volume":"9","author":"Sobacchi","year":"2013","journal-title":"Nat Rev Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1182\/blood-2006-12-061382","article-title":"Hematopoietic stem cell-targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc\/oc mice","volume":"109","author":"Johansson","year":"2007","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1089\/hum.2019.047","article-title":"Hematopoietic stem cell-targeted neonatal gene therapy with a clinically applicable lentiviral vector corrects osteopetrosis in oc\/oc mice","volume":"30","author":"L\u00f6fvall","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.07.026","article-title":"Lentiviral gene transfer of TCIRG1 into peripheral blood CD34+ cells restores osteoclast function in infantile malignant osteopetrosis","volume":"57","author":"Moscatelli","year":"2013","journal-title":"Bone."},{"key":"B33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00223-016-0187-6","article-title":"Regulation and function of lentiviral vector-mediated TCIRG1 expression in osteoclasts from patients with infantile malignant osteopetrosis: implications for gene therapy","volume":"99","author":"Thudium","year":"2016","journal-title":"Calcif Tissue Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13287-020-01701-y","article-title":"Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells","volume":"11","author":"Xian","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1002\/jbmr.1712","article-title":"Osteopetrosis rescue upon RANKL administration to Rankl-\/- mice: a new therapy for human RANKL-dependent ARO","volume":"27","author":"Lo Iacono","year":"2012","journal-title":"J Bone Miner Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/sctm.18-0085","article-title":"Mesenchymal stromal cell-seeded biomimetic scaffolds as a factory of soluble RANKL in rankl-deficient osteopetrosis","volume":"8","author":"Menale","year":"2019","journal-title":"Stem Cells Transl Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1038\/mtna.2015.21","article-title":"Effective small interfering RNA therapy to treat CLCN7-dependent autosomal dominant osteopetrosis type 2","volume":"4","author":"Capulli","year":"2015","journal-title":"Mol Ther Nucleic Acids."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/jbmr.2545","article-title":"Interferon Gamma, but not calcitriol improves the osteopetrotic phenotypes in ADO2 mice","volume":"30","author":"Alam","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone."},{"key":"B41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/jbmr.1794","article-title":"Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers","volume":"28","author":"Van Lierop","year":"2013","journal-title":"J Bone Miner Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone","volume":"112","author":"Tu","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone."},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor\u2013related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor\u2013related protein 5 gene results in the autosomal dominant high\u2013bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am J Hum Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jbspin.2004.10.008","article-title":"LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders","volume":"72","author":"Levasseur","year":"2005","journal-title":"Jt Bone Spine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell."},{"key":"B55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tem.2016.03.006","article-title":"Osteoporosis and bone mass disorders: from gene pathways to treatments","volume":"27","author":"Rivadeneira","year":"2016","journal-title":"Trends Endocrinol Metab."},{"key":"B56","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrg3315","article-title":"Genetics of osteoporosis from genome-wide association studies: advances and challenges","volume":"13","author":"Richards","year":"2012","journal-title":"Nat Rev Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2019.04.005","article-title":"The genetic architecture of osteoporosis and fracture risk","volume":"126","author":"Trajanoska","year":"2019","journal-title":"Bone."},{"key":"B58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fendo.2019.00337","article-title":"Recent advances in the genetics of fractures in osteoporosis","volume":"10","author":"Koromani","year":"2019","journal-title":"Front Endocrinol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajhg.2017.12.005","article-title":"Life-course genome-wide association study meta-analysis of total body BMD and assessment of age-specific effects","volume":"102","author":"Medina-Gomez","year":"2018","journal-title":"Am J Hum Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/ng.3949","article-title":"Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis","volume":"49","author":"Kemp","year":"2017","journal-title":"Nat Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41588-018-0302-x","article-title":"An atlas of genetic influences on osteoporosis in humans and mice","volume":"51","author":"Morris","year":"2019","journal-title":"Nat Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0200785","DOI":"10.1371\/journal.pone.0200785","article-title":"Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture","volume":"13","author":"Kim","year":"2018","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.coph.2014.03.006","article-title":"Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?","volume":"16","author":"Jepsen","year":"2014","journal-title":"Curr Opin Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.sbi.2014.10.003","article-title":"Extracellular modulators of Wnt signalling","volume":"29","author":"Malinauskas","year":"2014","journal-title":"Curr Opin Struct Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1001\/jama.292.17.2105","article-title":"Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes","volume":"292","author":"Ioannidis","year":"2004","journal-title":"J Am Med Assoc."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1371\/journal.pmed.0030090","article-title":"Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study","volume":"3","author":"Ralston","year":"2006","journal-title":"PLoS Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-145-4-200608150-00005","article-title":"The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis","volume":"145","author":"Uitterlinden","year":"2006","journal-title":"Ann Intern Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.bone.2007.11.007","article-title":"Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study","volume":"42","author":"Langdahl","year":"2008","journal-title":"Bone."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.299.11.1277","article-title":"Large-scale analysis of association between variants and osteoporosis","volume":"299","author":"van Meurs","year":"2008","journal-title":"JAMA."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1002548","DOI":"10.1371\/journal.pmed.1002548","article-title":"Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children","volume":"15","author":"Bonifacio","year":"2018","journal-title":"PLoS Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e002481","DOI":"10.1161\/CIRCGEN.119.002481","article-title":"Validation of genome-wide polygenic risk scores for coronary artery disease in french canadians","volume":"12","author":"W\u00fcnnemann","year":"2019","journal-title":"Circ Genomic Precis Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1176\/appi.ajp.2019.18091014","article-title":"Polygenic risk: predicting depression outcomes in clinical and epidemiological cohorts of youths","volume":"176","author":"Halldorsdottir","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1126\/science.aax4588","article-title":"Translational genomics and precision medicine: moving from the lab to the clinic","volume":"365","author":"Zeggini","year":"2019","journal-title":"Science."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1003152","DOI":"10.1371\/journal.pmed.1003152","article-title":"Development of a polygenic risk score to improve screening for fracture risk: a genetic risk prediction study","volume":"17","author":"Forgetta","year":"2020","journal-title":"PLoS Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u201cMendelian randomization\u201d: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11914-018-0467-3","article-title":"Using mendelian randomization to decipher mechanisms of bone disease","volume":"16","author":"Trajanoska","year":"2018","journal-title":"Curr Osteoporos Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3389\/fendo.2019.00807","article-title":"Use of Mendelian randomization to examine causal inference in osteoporosis","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Endocrinol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"k3225","DOI":"10.1136\/bmj.k3225","article-title":"Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study","volume":"362","author":"Trajanoska","year":"2018","journal-title":"BMJ."},{"key":"B80","doi-asserted-by":"publisher","first-page":"14410","DOI":"10.1136\/bmj.l4410","article-title":"Genetic predisposition to increased serum calcium, bone mineral density, and fracture risk in individuals with normal calcium levels: mendelian randomisation study","volume":"366","author":"Cerani","year":"2019","journal-title":"BMJ."},{"key":"B81","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jama.2017.8981","article-title":"Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction","volume":"318","author":"Larsson","year":"2017","journal-title":"JAMA."},{"key":"B82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1258\/136218004774202409","article-title":"Non-response to osteoporosis treatment","volume":"10","author":"Francis","year":"2004","journal-title":"J Br Menopause Soc."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.bone.2006.06.007","article-title":"Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis","volume":"39","author":"Gallagher","year":"2006","journal-title":"Bone."},{"key":"B84","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1210\/clinem\/dgz163","article-title":"Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT","volume":"105","author":"Ramchand","year":"","journal-title":"J Clin Endocrinol Metab."},{"key":"B85","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B86","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.coph.2014.05.003","article-title":"Stratified medicine approaches for the treatment of musculoskeletal disorders","volume":"16","author":"Hocking","year":"2014","journal-title":"Curr Opin Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2265.2003.01724.x","article-title":"Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with Bsml vitamin D receptor genotypes","volume":"58","author":"Palomba","year":"2003","journal-title":"Clin Endocrinol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00198-004-1800-5","article-title":"BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial","volume":"16","author":"Palomba","year":"2005","journal-title":"Osteoporos Int."},{"key":"B89","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s001980050231","article-title":"VDR genotype and response to etidronate therapy in late postmenopausal women","volume":"10","author":"Marc","year":"1999","journal-title":"Osteoporos Int."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1185\/03007990802352894","article-title":"Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis","volume":"24","author":"Marini","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00223-001-1035-9","article-title":"Colial Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy","volume":"70","author":"Qureshi","year":"2002","journal-title":"Calcif Tissue Int."},{"key":"B92","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/tpj.2010.88","article-title":"Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates","volume":"12","author":"Olmos","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0221511","DOI":"10.1371\/journal.pone.0221511","article-title":"Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis","volume":"14","author":"Marozik","year":"2019","journal-title":"PLoS ONE."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytoehrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bone.2018.06.004","article-title":"Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the rotterdam study","volume":"114","author":"Trajanoska","year":"2018","journal-title":"Bone."},{"key":"B97","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAXTM and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"key":"B98","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00774-009-0057-7","article-title":"The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis","volume":"27","author":"Yan","year":"2009","journal-title":"J Bone Miner Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial","volume":"136","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int."},{"key":"B106","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1210\/jc.82.1.265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women 1","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"B107","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J Bone Miner Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1359\/jbmr.040116","article-title":"Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study","volume":"19","author":"McCloskey","year":"2004","journal-title":"J Bone Miner Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"B113","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric."},{"key":"B114","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos Int."},{"key":"B115","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone."},{"key":"B121","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"J Am Med Assoc."},{"key":"B123","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/archinte.164.8.871","article-title":"A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women","volume":"164","author":"Reid","year":"2004","journal-title":"Arch Intern Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","article-title":"Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int."},{"key":"B126","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/jbmr.252","article-title":"Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis","volume":"26","author":"Itabashi","year":"2011","journal-title":"J Bone Miner Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Min Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/jbmr.191","article-title":"Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women","volume":"26","author":"Cummings","year":"2011","journal-title":"J Bone Miner Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"B131","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1210\/jc.2013-2020","article-title":"Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial","volume":"98","author":"Bonnick","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B133","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B135","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on newvertebral fractures in postmenopausalwomen with osteoporosis a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"key":"B136","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00223-013-9777-8","article-title":"Once-weekly injection of low-dose teriparatide (28","volume":"94","author":"Fujita","year":"2014","journal-title":"Calcif Tissue Int."},{"key":"B137","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric."},{"key":"B141","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S2665-9913(19)30136-5","article-title":"The crisis of inadequate treatment in osteoporosis","volume":"2","author":"Roux","year":"2020","journal-title":"Lancet Rhumatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: phase II and phase III attrition rates 2011-2012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov."},{"key":"B143","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","article-title":"Phase II and phase III failures: 2013-2015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B144","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet."},{"key":"B145","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet."},{"key":"B146","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat Genet."},{"key":"B147","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/cge.12465","article-title":"From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis","volume":"86","author":"Okada","year":"2014","journal-title":"Clin Genet."},{"key":"B148","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00439-017-1854-z","article-title":"The ubiquity of pleiotropy in human disease","volume":"137","author":"Chesmore","year":"2018","journal-title":"Hum Genet."},{"key":"B150","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1586\/eci.10.64","article-title":"Duloxetine for the treatment of fibromyalgia","volume":"6","author":"Wright","year":"2010","journal-title":"Expert Rev Clin Immunol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/1759720X13508508","article-title":"Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee","volume":"5","author":"Brown","year":"2013","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology."},{"key":"B154","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2017.02.021","article-title":"Giant cell tumour of bone in the denosumab era","volume":"77","author":"van der Heijden","year":"2017","journal-title":"Eur J Cancer."},{"key":"B155","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1470-2045(10)70076-0","article-title":"RANK and RANKL expression in giant-cell tumour of bone","volume":"11","author":"Roux","year":"2010","journal-title":"Lancet Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature."},{"key":"B157","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B159","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center","volume":"28","author":"Afzal","year":"2018","journal-title":"Melanoma Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jamainternmed.2014.3634","article-title":"Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid","volume":"174","author":"Hue","year":"2014","journal-title":"JAMA Intern Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"72147","DOI":"10.18632\/oncotarget.20046","article-title":"Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer","volume":"8","author":"Kobayashi","year":"2017","journal-title":"Oncotarget."},{"key":"B163","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer."},{"key":"B164","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbz122","article-title":"An omics perspective on drug target discovery platforms","author":"Paananen","year":"2019","journal-title":"Brief Bioinform"},{"key":"B166","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.drudis.2017.12.001","article-title":"Network-based technologies for early drug discovery","volume":"23","author":"Fotis","year":"2018","journal-title":"Drug Discov Today."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-8955-3_1","article-title":"Methods for discovering and targeting druggable protein-protein interfaces and their application to repurposing","volume":"1903","author":"Ozdemir","year":"2019","journal-title":"Methods Mol Biol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci."},{"key":"B169","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/wellcomeopenres.15334.2","article-title":"Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes","volume":"4","author":"Walker","year":"2019","journal-title":"Wellcome Open Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities","volume":"46","author":"Walker","year":"2017","journal-title":"Int J Epidemiol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt.2151","article-title":"Use of genome-wide association studies for drug repositioning","volume":"30","author":"Sanseau","year":"2012","journal-title":"Nat Biotechnol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/nbt.2758","article-title":"Rational drug repositioning by medical genetics","volume":"31","author":"Wang","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using mendelian randomization","volume":"11","author":"Schmidt","year":"","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases","volume":"2020","author":"Zheng","year":"2020","journal-title":"Nat Genet."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e0196713","DOI":"10.1371\/journal.pone.0196713","article-title":"Long-term effect of statins on the risk of new-onset osteoporosis: a nationwide population-based cohort study","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS ONE."},{"key":"B179","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1001\/archinte.165.17.2007","article-title":"Statin use and fracture risk: study of a US veterans population","volume":"165","author":"Scranton","year":"2005","journal-title":"Arch Intern Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"dyz145","DOI":"10.1093\/ije\/dyz145","article-title":"Positive effects of low LDL-C and statins on bone mineral density: an integrated epidemiological observation analysis and mendelian randomization study","volume":"13","author":"Li","year":"2019","journal-title":"Int J Epidemiol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/jbmr.3989","article-title":"The effect of plasma lipids and lipid-lowering interventions on bone mineral density: a mendelian randomization study","volume":"35","author":"Zheng","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science."},{"key":"B184","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1515\/bc.2011.042","article-title":"Clustered regularly interspaced short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense mechanism in prokaryotes","volume":"392","author":"Al-Attar","year":"2011","journal-title":"Biol Chem."},{"key":"B185","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"B187","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2019.00277","article-title":"Mouse models and online resources for functional analysis of osteoporosis genome-wide association studies","volume":"10","author":"Maynard","year":"2019","journal-title":"Front Endocrinol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2019.00006","article-title":"Zebrafish as an emerging model for osteoporosis: a primary testing platform for screening new osteo-active compounds","volume":"10","author":"Bergen","year":"2019","journal-title":"Front Endocrinol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.csbj.2019.06.006","article-title":"The progress of CRISPR\/Cas9-mediated gene editing in generating mouse\/zebrafish models of human skeletal diseases","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J."},{"key":"B190","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2017.11.013","article-title":"Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice","volume":"107","author":"Rauch","year":"2018","journal-title":"Bone."},{"key":"B191","doi-asserted-by":"publisher","first-page":"14165","DOI":"10.1074\/jbc.RA118.004242","article-title":"The lateral meningocele syndrome mutation causes marked osteopenia in mice","volume":"293","author":"Canalis","year":"2018","journal-title":"J Biol Chem."},{"key":"B192","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.devcel.2018.07.024","article-title":"Combinatorial CRISPR\/Cas9 approach to elucidate a far-upstream enhancer complex for tissue-specific Sox9 expression","volume":"46","author":"Mochizuki","year":"2018","journal-title":"Dev Cell."},{"key":"B193","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type v","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.7150\/thno.17140","article-title":"Deficiency of ATP6V1H causes bone loss by inhibiting bone resorption and bone formation through the TGF-\u03b21 pathway","volume":"6","author":"Duan","year":"2016","journal-title":"Theranostics."},{"key":"B195","doi-asserted-by":"publisher","first-page":"e1006624","DOI":"10.1371\/journal.pgen.1006624","article-title":"ATP6V1H deficiency impairs bone development through activation of MMP9 and MMP13","volume":"13","author":"Zhang","year":"2017","journal-title":"PLoS Genet."},{"key":"B196","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11914-018-0459-3","article-title":"Recent advances and future of gene therapy for bone regeneration","volume":"16","author":"Shapiro","year":"2018","journal-title":"Curr Osteoporos Rep."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.556610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T06:53:19Z","timestamp":1602658399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.556610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":196,"alternative-id":["10.3389\/fendo.2020.556610"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.556610","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"article-number":"556610"}}